These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27132951)

  • 1. Relation of cerebrospinal fluid/plasma HIV-RNA discordance with neurocognitive impairment.
    Cárdenas G; López-González M; Monzón-Falconi JF; Soto-Hernández JL; Perales-Martínez D; López-Vejar C
    Natl Med J India; 2015; 28(5):228-32. PubMed ID: 27132951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
    Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
    Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
    J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV encephalitis in a patient on antiretroviral therapy: a case report.
    Hlebowicz M; Parczewski M; Jakubowski P
    Int J STD AIDS; 2019 May; 30(6):617-619. PubMed ID: 30722753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
    Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
    Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.
    Bogoch II; Davis BT; Venna N
    J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.
    Calcagno A; Simiele M; Alberione MC; Bracchi M; Marinaro L; Ecclesia S; Di Perri G; D'Avolio A; Bonora S
    Clin Infect Dis; 2015 Jan; 60(2):311-7. PubMed ID: 25281609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical and virological correlation between the cerebrospinal fluid and blood of HIV-infected children].
    Sáez-Llorens X; Castrejón de Wong MC; Castaño E; de Suman O; Báez de Ulloa C; Redondo W; Espino M
    Rev Med Panama; 2001; 26():13-8. PubMed ID: 16161718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.
    Edén A; Fuchs D; Hagberg L; Nilsson S; Spudich S; Svennerholm B; Price RW; Gisslén M
    J Infect Dis; 2010 Dec; 202(12):1819-25. PubMed ID: 21050119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid.
    Cinque P; Presi S; Bestetti A; Pierotti C; Racca S; Boeri E; Morelli P; Carrera P; Ferrari M; Lazzarin A
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):377-83. PubMed ID: 11282006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cerebrospinal fluid viral load in HIV-1 positive hemophilic patients treated with HAART].
    Corti ME; Villafañe MF; Baré P; Alves Rosa F; Cermelj M; Candela M; Pérez Bianco R; Tezanos Pinto M
    Medicina (B Aires); 2001; 61(6):821-4. PubMed ID: 11808421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects.
    Pérez-Valero I; Ellis R; Heaton R; Deutsch R; Franklin D; Clifford DB; Collier A; Gelman B; Marra C; McCutchan JA; Navis A; Sacktor N; Simpson D; Grant I; Letendre S
    AIDS; 2019 Mar; 33(3):475-481. PubMed ID: 30702516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
    Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
    Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.
    Antinori A; Perno CF; Giancola ML; Forbici F; Ippolito G; Hoetelmans RM; Piscitelli SC
    Clin Infect Dis; 2005 Dec; 41(12):1787-93. PubMed ID: 16288405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia.
    Motta I; Allice T; Romito A; Ferrara M; Ecclesia S; Imperiale D; Ghisetti V; Di Perri G; Bonora S; Calcagno A
    Antivir Ther; 2017; 22(6):539-543. PubMed ID: 28198350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.
    Meynard JL; Bouteloup V; Landman R; Bonnard P; Baillat V; Cabie A; Kolta S; Izopet J; Taburet AM; Mercie P; Chene G; Girard PM;
    J Antimicrob Chemother; 2010 Nov; 65(11):2436-44. PubMed ID: 20843990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.
    Di Yacovo MS; Moltó J; Ferrer E; Curran A; Else L; Gisslén M; Clotet B; Tiraboschi JM; Niubò J; Vila A; Zetterberg H; Back D; Podzamczer D
    J Antimicrob Chemother; 2015 May; 70(5):1513-6. PubMed ID: 25608583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
    Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
    J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.